2 3 5 6 7 8 10 11 13 15 19 20 36 37
前 言 HER2 HER2 1 HER2 2 HER2 3,4 Tykerb lapatinib HER2 HER2 5 2
HER2 HER2 HER2 HER2 HER2 HER1 EGFR 4,6 HER2 3
5 Xeloda capecitabine HER2 Herceptin trastuzumab Femara letrozole HER2 4
HER2 5 7,8 4.4 8.4 18.6 75.0 56.4 22% 8 (%) 100 80 60 40 20 + 75.0 56.4 HR = 0.78 p = 0.023 0 0 20 40 60 80 100 120 140 160 180 200 220 240 5
HER2 5 Femara letrozole 9,10 3 3 8.2 2 3 9 100 80 60 40 20 (%) 3.0 + 8.2 HR = 0.71 p < 0.019 0 0 5 10 15 20 25 30 35 40 45 50 6
5 21 21 1-14 15-21 30 5 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 5 7
5 8
1 5 5 5 5 5 20-35 20-35 9
11 5 10
11 12 50% 50% 11
11 SPF 30 1-2 12
13
11 SPF 30 30 1-2 14
11 7-9 11 12 4 4 4-6 4 6 24 7 7 24 15
11 20-35 8-10 12-14 16
13,14 13,14 17
18
13,14 13,14 1 19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
SPF 30 A C E 36
http://www.breastcf.org.tw http://www.tbca-npo.org.tw http://www.ntuh.gov.tw/bc/ default.aspx http://www.kfsyscc.org/cancer/ breast-cancer/intro 37